These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 24910416

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients.
    Paluch-Shimon S, Ben-Baruch N, Wolf I, Zach L, Kopolovic J, Kruglikova A, Modiano T, Yosepovich A, Catane R, Kaufman B.
    Am J Clin Oncol; 2009 Oct; 32(5):504-8. PubMed ID: 19564785
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The impacts of MACC1 gene polymorphisms on urothelial cell carcinoma susceptibility and clinicopathologic characteristics in Taiwan.
    Chang LW, Hung SC, Chou YE, Chen CS, Li JR, Lin CY, Wang SS, Yang SF.
    J Cancer; 2023 Oct; 14(18):3532-3538. PubMed ID: 38021160
    [Abstract] [Full Text] [Related]

  • 26. Genetic polymorphism of miR-196a as a prognostic biomarker for early breast cancer.
    Lee SJ, Seo JW, Chae YS, Kim JG, Kang BW, Kim WW, Jung JH, Park HY, Jeong JY, Park JY.
    Anticancer Res; 2014 Jun; 34(6):2943-9. PubMed ID: 24922658
    [Abstract] [Full Text] [Related]

  • 27. Association of matrix metalloproteinase-8 gene variation with breast cancer prognosis.
    Decock J, Long JR, Laxton RC, Shu XO, Hodgkinson C, Hendrickx W, Pearce EG, Gao YT, Pereira AC, Paridaens R, Zheng W, Ye S.
    Cancer Res; 2007 Nov 01; 67(21):10214-21. PubMed ID: 17974962
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
    Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN, National Cancer Institute of Canada Clinical Trials Group.
    N Engl J Med; 2006 May 18; 354(20):2103-11. PubMed ID: 16707747
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.
    Cresti N, Lee J, Rourke E, Televantou D, Jamieson D, Verrill M, Boddy AV.
    Eur J Cancer; 2016 Mar 18; 55():27-37. PubMed ID: 26773371
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
    Papadopoulou E, Tripsianis G, Anagnostopoulos K, Tentes I, Kakolyris S, Galazios G, Sivridis E, Simopoulos K, Kortsaris A.
    Neoplasma; 2008 Mar 18; 55(2):113-21. PubMed ID: 18237248
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.